PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
FibroGen, Inc. (FGEN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS31572Q8087
CUSIP31572Q808
SectorHealthcare
IndustryBiotechnology
IPO DateNov 14, 2014

Highlights

Market Cap$32.67M
EPS (TTM)-$1.70
Total Revenue (TTM)$133.68M
Gross Profit (TTM)$97.34M
EBITDA (TTM)-$92.70M
Year Range$0.29 - $2.93
Target Price$0.60
Short %4.73%
Short Ratio4.28

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: FGEN vs. FAT, FGEN vs. DHC, FGEN vs. VTSAX, FGEN vs. SCHD, FGEN vs. VUG, FGEN vs. VPU

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in FibroGen, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%JuneJulyAugustSeptemberOctoberNovember
-71.92%
10.27%
FGEN (FibroGen, Inc.)
Benchmark (^GSPC)

Returns By Period

FibroGen, Inc. had a return of -63.29% year-to-date (YTD) and -49.74% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-63.29%19.77%
1 month-11.26%-0.67%
6 months-71.95%10.27%
1 year-49.74%31.07%
5 years (annualized)-61.59%13.22%
10 years (annualized)N/A10.92%

Monthly Returns

The table below presents the monthly returns of FGEN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024116.63%-10.94%37.43%-52.34%7.14%-25.64%-39.47%-32.31%9.25%-24.54%-63.29%
202347.32%-5.93%-15.95%-8.25%0.76%-84.35%-23.70%-53.40%-10.11%-37.30%2.11%60.45%-94.47%
20227.02%-6.76%-14.57%-22.63%5.81%7.32%19.13%-1.11%4.58%25.13%-11.73%11.48%13.62%
202129.90%3.84%-30.62%-35.70%-4.79%25.32%-51.18%-10.54%-12.12%8.81%12.50%12.71%-61.98%
2020-2.42%-0.12%-16.87%6.16%-9.35%21.20%-0.15%10.77%-8.28%-6.66%7.63%-10.22%-13.52%
201922.62%1.85%-5.97%-14.02%-22.45%24.67%4.60%-5.50%-17.20%5.87%8.22%1.23%-7.32%
201823.52%-5.89%-16.15%-1.62%18.59%16.14%0.80%-3.09%-0.65%-29.43%1.14%6.73%-2.36%
20175.84%10.38%-1.40%13.59%-6.07%22.81%5.73%41.14%11.62%3.81%-14.95%-0.21%121.50%
2016-33.44%-14.55%22.85%-15.45%3.67%-12.06%16.58%-9.51%19.58%-20.05%33.84%-3.39%-29.77%
20158.01%7.75%-1.38%-25.91%-21.68%29.05%-1.06%5.38%-10.53%6.34%27.58%2.45%11.45%
20142.95%20.71%24.27%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of FGEN is 30, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of FGEN is 3030
Combined Rank
The Sharpe Ratio Rank of FGEN is 2626Sharpe Ratio Rank
The Sortino Ratio Rank of FGEN is 4141Sortino Ratio Rank
The Omega Ratio Rank of FGEN is 4040Omega Ratio Rank
The Calmar Ratio Rank of FGEN is 1818Calmar Ratio Rank
The Martin Ratio Rank of FGEN is 2525Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for FibroGen, Inc. (FGEN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


FGEN
Sharpe ratio
The chart of Sharpe ratio for FGEN, currently valued at -0.27, compared to the broader market-4.00-2.000.002.00-0.27
Sortino ratio
The chart of Sortino ratio for FGEN, currently valued at 0.61, compared to the broader market-4.00-2.000.002.004.000.61
Omega ratio
The chart of Omega ratio for FGEN, currently valued at 1.08, compared to the broader market0.501.001.502.001.08
Calmar ratio
The chart of Calmar ratio for FGEN, currently valued at -0.43, compared to the broader market0.002.004.006.00-0.43
Martin ratio
The chart of Martin ratio for FGEN, currently valued at -0.75, compared to the broader market-10.000.0010.0020.0030.00-0.75
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.67, compared to the broader market-4.00-2.000.002.002.67
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.55, compared to the broader market-4.00-2.000.002.004.003.55
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.50, compared to the broader market0.501.001.502.001.50
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 3.45, compared to the broader market0.002.004.006.003.45
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 17.04, compared to the broader market-10.000.0010.0020.0030.0017.04

Sharpe Ratio

The current FibroGen, Inc. Sharpe ratio is -0.27. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of FibroGen, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.27
2.67
FGEN (FibroGen, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


FibroGen, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-99.52%
-2.59%
FGEN (FibroGen, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the FibroGen, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the FibroGen, Inc. was 99.56%, occurring on Oct 28, 2024. The portfolio has not yet recovered.

The current FibroGen, Inc. drawdown is 99.52%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.56%Jul 9, 20181588Oct 28, 2024
-59.26%Jan 8, 2015273Feb 8, 2016378Aug 8, 2017651
-30.2%Oct 5, 201750Dec 14, 201729Jan 29, 201879
-27.17%Jan 30, 201847Apr 6, 201851Jun 19, 201898
-17.68%Aug 9, 20176Aug 16, 201717Sep 11, 201723

Volatility

Volatility Chart

The current FibroGen, Inc. volatility is 21.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%JuneJulyAugustSeptemberOctoberNovember
21.50%
3.11%
FGEN (FibroGen, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of FibroGen, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for FibroGen, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items